Reneo Pharmaceuticals, Inc.: management transactions · United States · SEC (Form 4)

About Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. is a United States-based biopharmaceutical company that has been listed on the Nasdaq market. Historically, the company was built around developing therapies for rare genetic mitochondrial diseases, targeting areas of high unmet medical need. Reneo began operations in 2014 and centered its early strategy on a lead asset, REN001, which was being advanced across multiple rare metabolic disease indications. The company is headquartered in Irvine, California, and its operating footprint has primarily been tied to clinical development, regulatory work, and corporate functions rather than commercial manufacturing or broad sales infrastructure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1637715/000095017023014812/rphm_2022_annual_report.pdf?utm_source=openai)) From an industry perspective, Reneo has been a clinical-stage biotech, meaning its value proposition has depended on research execution, intellectual property, and clinical milestones rather than recurring product revenue. Its competitive position was therefore defined less by scale and more by scientific differentiation in niche orphan-disease markets. The company’s development focus included primary mitochondrial myopathies, long-chain fatty acid oxidation disorders, and glycogen storage disease type V (McArdle disease), all of which represent relatively small patient populations but meaningful commercial opportunities if clinical data and regulatory approval can be secured. ([nasdaq.com](https://www.nasdaq.com/press-release/vtv-therapeutics-announces-2021-first-quarter-financial-results-and-provides?utm_source=openai)) A major recent development was the strategic pivot announced in 2024: Reneo entered into, and later secured shareholder approval for, an all-stock merger with OnKure, a clinical-stage oncology company focused on precision medicines. The companies announced that the combined entity would trade on Nasdaq under the ticker OKUR and adopt the name OnKure Therapeutics, Inc. The merger was framed as a way to combine resources and shift the public-company platform toward oncology, while Reneo’s own legacy mitochondrial program was being deemphasized. Reneo’s second-quarter 2024 results also noted the suspension of mavodelpar development activities and associated cost reductions, underscoring a transition away from the original strategy. ([nasdaq.com](https://www.nasdaq.com/press-release/reneo-pharmaceuticals-announces-stockholder-approval-merger-onkure-2024-10-02?utm_source=openai)) For French-speaking investors, Reneo should be viewed as a very small-cap U.S. biotech on Nasdaq, with a history rooted in rare-disease drug development and a recent corporate transformation toward oncology. The core investment case has been driven by pipeline optionality, clinical execution risk, and balance-sheet considerations rather than established operating profits. In practical terms, the company’s profile is that of a transitional biotech platform: scientifically specialized, high-risk, and highly dependent on strategic transactions and future clinical readouts.